Inotiv, Inc. (NOTVQ) - Net Assets
Based on the latest financial reports, Inotiv, Inc. (NOTVQ) has net assets worth $77.10 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($702.42 Million) and total liabilities ($625.32 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore NOTVQ net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $77.10 Million |
| % of Total Assets | 10.98% |
| Annual Growth Rate | 11.24% |
| 5-Year Change | 29.39% |
| 10-Year Change | 1723.92% |
| Growth Volatility | 242.93 |
Inotiv, Inc. - Net Assets Trend (1997–2025)
This chart illustrates how Inotiv, Inc.'s net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Inotiv, Inc. to measure how much of total assets are equity-financed.
Annual Net Assets for Inotiv, Inc. (1997–2025)
The table below shows the annual net assets of Inotiv, Inc. from 1997 to 2025. For live market cap and overall valuation, see Inotiv, Inc. market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $136.03 Million | -20.22% |
| 2024-09-30 | $170.50 Million | -36.50% |
| 2023-09-30 | $268.49 Million | -25.37% |
| 2022-09-30 | $359.77 Million | +242.22% |
| 2021-09-30 | $105.13 Million | +1283.99% |
| 2020-09-30 | $7.60 Million | -29.08% |
| 2019-09-30 | $10.71 Million | -1.60% |
| 2018-09-30 | $10.88 Million | +28.55% |
| 2017-09-30 | $8.47 Million | +13.53% |
| 2016-09-30 | $7.46 Million | -30.42% |
| 2015-09-30 | $10.72 Million | +12.40% |
| 2014-09-30 | $9.54 Million | +0.81% |
| 2013-09-30 | $9.46 Million | -1.37% |
| 2012-09-30 | $9.59 Million | -38.47% |
| 2011-09-30 | $15.59 Million | +46.11% |
| 2010-09-30 | $10.67 Million | -18.70% |
| 2009-09-30 | $13.12 Million | -26.27% |
| 2008-09-30 | $17.80 Million | -4.09% |
| 2007-09-30 | $18.55 Million | +6.92% |
| 2006-09-30 | $17.35 Million | -11.45% |
| 2005-09-30 | $19.60 Million | +0.92% |
| 2004-09-30 | $19.42 Million | -1.55% |
| 2003-09-30 | $19.73 Million | +4.38% |
| 2002-09-30 | $18.90 Million | +5.99% |
| 2001-09-30 | $17.83 Million | +11.01% |
| 2000-09-30 | $16.06 Million | -7.69% |
| 1999-09-30 | $17.40 Million | +3.57% |
| 1998-09-30 | $16.80 Million | +143.48% |
| 1997-09-30 | $6.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Inotiv, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12716.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.55 Million | 6.29% |
| Other Comprehensive Income | $2.23 Million | 1.64% |
| Other Components | $756.06 Million | 555.81% |
| Total Equity | $136.03 Million | 100.00% |
Inotiv, Inc. Competitors by Market Cap
The table below lists competitors of Inotiv, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
HODL SPAC EUROPE AB
F:NW1
|
$392.16K |
|
Chelverton UK Dividend Trust PLC
LSE:SDV
|
$393.34K |
|
Anexo Group Plc
LSE:ANX
|
$393.45K |
|
Bezant Resources Plc
LSE:BZT
|
$394.11K |
|
GRIT Real Estate Income Group
LSE:GR1T
|
$388.80K |
|
Hemogenyx Pharmaceuticals PLC
LSE:HEMO
|
$387.47K |
|
ONETECH SOLUTIONS HOLDINGS BERHAD
KLSE:03041
|
$386.39K |
|
Valion Bio Inc
NASDAQ:VBIO
|
$384.85K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Inotiv, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 170,504,000 to 136,028,000, a change of -34,476,000 (-20.2%).
- Net loss of 68,625,000 reduced equity.
- New share issuances of 27,524,000 increased equity.
- Other comprehensive income increased equity by 816,000.
- Other factors increased equity by 5,809,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-68.62 Million | -50.45% |
| Share Issuances | $27.52 Million | +20.23% |
| Other Comprehensive Income | $816.00K | +0.6% |
| Other Changes | $5.81 Million | +4.27% |
| Total Change | $- | -20.22% |
Book Value vs Market Value Analysis
This analysis compares Inotiv, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-09-30 | $1.57 | $0.01 | x |
| 1998-09-30 | $3.82 | $0.01 | x |
| 1999-09-30 | $3.72 | $0.01 | x |
| 2000-09-30 | $3.53 | $0.01 | x |
| 2001-09-30 | $3.88 | $0.01 | x |
| 2002-09-30 | $4.09 | $0.01 | x |
| 2003-09-30 | $4.22 | $0.01 | x |
| 2004-09-30 | $4.00 | $0.01 | x |
| 2005-09-30 | $4.02 | $0.01 | x |
| 2006-09-30 | $3.55 | $0.01 | x |
| 2007-09-30 | $3.74 | $0.01 | x |
| 2008-09-30 | $3.58 | $0.01 | x |
| 2009-09-30 | $2.67 | $0.01 | x |
| 2010-09-30 | $2.17 | $0.01 | x |
| 2011-09-30 | $2.75 | $0.01 | x |
| 2012-09-30 | $1.34 | $0.01 | x |
| 2013-09-30 | $1.13 | $0.01 | x |
| 2014-09-30 | $1.20 | $0.01 | x |
| 2015-09-30 | $1.22 | $0.01 | x |
| 2016-09-30 | $0.92 | $0.01 | x |
| 2017-09-30 | $0.97 | $0.01 | x |
| 2018-09-30 | $1.24 | $0.01 | x |
| 2019-09-30 | $1.03 | $0.01 | x |
| 2020-09-30 | $0.70 | $0.01 | x |
| 2021-09-30 | $7.58 | $0.01 | x |
| 2022-09-30 | $14.80 | $0.01 | x |
| 2023-09-30 | $10.50 | $0.01 | x |
| 2024-09-30 | $6.58 | $0.01 | x |
| 2025-09-30 | $4.19 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Inotiv, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -50.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -13.38%
- • Asset Turnover: 0.67x
- • Equity Multiplier: 5.67x
- Recent ROE (-50.45%) is below the historical average (-15.85%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | 10.14% | 4.70% | 0.94x | 2.30x | $10.00K |
| 1998 | 2.38% | 2.20% | 0.82x | 1.33x | $-1.28 Million |
| 1999 | 3.45% | 3.02% | 0.76x | 1.51x | $-1.14 Million |
| 2000 | -8.60% | -7.19% | 0.72x | 1.66x | $-2.99 Million |
| 2001 | 9.91% | 6.99% | 0.90x | 1.57x | $-16.28K |
| 2002 | 5.64% | 4.02% | 0.79x | 1.77x | $-823.39K |
| 2003 | 0.44% | 0.29% | 0.66x | 2.28x | $-1.89 Million |
| 2004 | -1.05% | -0.55% | 0.79x | 2.41x | $-2.15 Million |
| 2005 | -0.52% | -0.24% | 0.89x | 2.44x | $-2.06 Million |
| 2006 | -15.04% | -6.06% | 1.02x | 2.44x | $-4.35 Million |
| 2007 | 4.99% | 2.05% | 1.08x | 2.27x | $-929.40K |
| 2008 | -8.37% | -3.57% | 1.03x | 2.27x | $-3.27 Million |
| 2009 | -41.64% | -17.19% | 0.98x | 2.48x | $-6.78 Million |
| 2010 | -25.23% | -9.35% | 0.97x | 2.79x | $-3.76 Million |
| 2011 | 3.48% | 1.64% | 1.02x | 2.08x | $-1.02 Million |
| 2012 | -66.63% | -22.65% | 1.05x | 2.81x | $-7.35 Million |
| 2013 | 8.17% | 3.50% | 0.86x | 2.71x | $-172.90K |
| 2014 | -11.22% | -4.35% | 1.03x | 2.49x | $-2.02 Million |
| 2015 | 10.16% | 4.80% | 0.95x | 2.22x | $17.20K |
| 2016 | -43.31% | -15.80% | 0.97x | 2.83x | $-3.98 Million |
| 2017 | 10.44% | 3.65% | 1.19x | 2.41x | $37.30K |
| 2018 | -1.78% | -0.74% | 0.84x | 2.87x | $-1.28 Million |
| 2019 | -7.38% | -1.81% | 1.04x | 3.92x | $-1.86 Million |
| 2020 | -61.68% | -7.75% | 0.98x | 8.11x | $-5.44 Million |
| 2021 | 10.36% | 12.16% | 0.28x | 3.06x | $382.20K |
| 2022 | -93.59% | -61.58% | 0.57x | 2.67x | $-373.30 Million |
| 2023 | -39.06% | -18.37% | 0.67x | 3.18x | $-132.06 Million |
| 2024 | -63.60% | -22.10% | 0.63x | 4.58x | $-125.50 Million |
| 2025 | -50.45% | -13.38% | 0.67x | 5.67x | $-82.23 Million |
Industry Comparison
This section compares Inotiv, Inc.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $411,604,989
- Average return on equity (ROE) among peers: -98.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Inotiv, Inc. (NOTVQ) | $77.10 Million | 10.14% | 8.11x | $390.42K |
| Agilent Technologies Inc (A) | $3.38 Billion | 15.14% | 0.61x | $43.76 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.49 Million | -115.35% | 0.92x | $10.52 Million |
| Applied DNA Sciences Inc (APDN) | $4.62 Million | -383.15% | 0.81x | $3.99 Million |
| Biodesix Inc (BDSX) | $-228.54 Million | 0.00% | 0.00x | $247.95 Million |
| bioAffinity Technologies, Inc. (BIAF) | $4.86 Million | -163.47% | 0.69x | $1.80 Million |
| Biocept Inc. (BIOCQ) | $37.48 Million | -7.53% | 0.61x | $262.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $480.11 Million | 1.55% | 0.32x | $4.05 Billion |
| Burning Rock Biotech Ltd (BNR) | $168.49 Million | -77.91% | 1.38x | $86.20 Million |
| CareDx Inc (CDNA) | $261.33 Million | -72.81% | 0.79x | $2.42 Billion |
| Check Cap Ltd (CHEK) | $2.23 Million | -183.03% | 2.50x | $9.42 Million |
About Inotiv, Inc.
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences researc… Read more